Investor
BIOS Capital Management, LP
CIK 0001813845 · filed 2026-05-13 · SEC filing
13F book
$52.9M
Positions
6
Largest name
52.1%
Actuate Therapeutics, Inc. · ACTU
Est. mark
−$29.5M
Price effect on 6 names still held. Flow −$260.8K.
| Name | Ticker | Shares | Value | Weight | Est. mark | Change |
|---|---|---|---|---|---|---|
| Actuate Therapeutics, Inc. | ACTU | 10M | $27.5M | 52.1% | −$34M | Held |
| Opus Genetics, Inc. | IRD | 3.68M | $16.8M | 31.7% | $9.36M | Held |
| Cognition Therapeutics Inc | CGTX | 6M | $4.56M | 8.6% | −$3.54M | Held |
| Rein Therapeutics, Inc. | RNTX | 1.98M | $2.58M | 4.9% | $236.7K | Added$615.8K |
| Lantern Pharma Inc. | LTRN | 864.4K | $1.18M | 2.2% | −$1.43M | Cut−$1.87M |
| In8bio, Inc. | INAB | 167.8K | $248.4K | 0.5% | −$144.3K | Cut−$344.6K |
Positions as of Q1 2026. 13F filings arrive up to 45 days after quarter-end and omit shorts. Values are quarter-end marks, as filed. Estimated mark is the price effect on shares still held — not realized P&L or investment advice.